Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 1
1976 2
1977 2
1978 1
1979 2
1980 3
1981 4
1982 5
1983 4
1984 4
1985 13
1986 7
1987 11
1988 14
1989 10
1990 13
1991 17
1992 20
1993 19
1994 24
1995 22
1996 24
1997 14
1998 23
1999 26
2000 21
2001 35
2002 38
2003 38
2004 37
2005 53
2006 60
2007 68
2008 75
2009 83
2010 81
2011 92
2012 117
2013 109
2014 116
2015 113
2016 139
2017 126
2018 145
2019 161
2020 189
2021 179
2022 156
2023 162
2024 61

Text availability

Article attribute

Article type

Publication date

Search Results

2,368 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Increased risk for multiple myeloma"
Page 1
Roadmap to cure multiple myeloma.
Rodriguez-Otero P, Paiva B, San-Miguel JF. Rodriguez-Otero P, et al. Cancer Treat Rev. 2021 Nov;100:102284. doi: 10.1016/j.ctrv.2021.102284. Epub 2021 Aug 31. Cancer Treat Rev. 2021. PMID: 34597912 Free article. Review.
Despite significant advances in the treatment of multiple myeloma which had led to unprecedented rates of response and survival, patients still relapse, and cure remains elusive. We propose in this review a roadmap to achieve the dream of cure for multiple …
Despite significant advances in the treatment of multiple myeloma which had led to unprecedented rates of response and surviva …
Multiple myeloma.
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Kumar SK, et al. Nat Rev Dis Primers. 2017 Jul 20;3:17046. doi: 10.1038/nrdp.2017.46. Nat Rev Dis Primers. 2017. PMID: 28726797 Review.
Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of undetermined significance and smouldering multiple myeloma is important, as observation is the standard for those conditions. ...S …
Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of unde …
Multiple myeloma.
Röllig C, Knop S, Bornhäuser M. Röllig C, et al. Lancet. 2015 May 30;385(9983):2197-208. doi: 10.1016/S0140-6736(14)60493-1. Epub 2014 Dec 23. Lancet. 2015. PMID: 25540889 Review.
Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. ...Present clinical research focuses …
Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically …
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications.
Bernstein ZS, Kim EB, Raje N. Bernstein ZS, et al. Cells. 2022 Jul 27;11(15):2308. doi: 10.3390/cells11152308. Cells. 2022. PMID: 35954151 Free PMC article. Review.
Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. ...Approximately half of patients with bone disease will experience skeletal-related events (SREs), such as spinal cord …
Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized with …
IMWG consensus on risk stratification in multiple myeloma.
Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. Chng WJ, et al. Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Leukemia. 2014. PMID: 23974982 Review.
Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. ...At the same time, these risk categories serve as a framework to rationalize the use of therapies....
Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response t …
The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.
Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS; Non-communicable Disease Global Health Research Group, Association of Pacific Rim Universities. Huang J, et al. Lancet Haematol. 2022 Sep;9(9):e670-e677. doi: 10.1016/S2352-3026(22)00165-X. Epub 2022 Jul 14. Lancet Haematol. 2022. PMID: 35843248
BACKGROUND: Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence cases leukaemia, lymphoma, and multiple myeloma in 2020. ...The overall decreasing global trend of multiple myeloma mortality was more evident in women. L …
BACKGROUND: Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence cases leukaemia, lymphoma, and multiple …
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley DC, Keller J, Thomas T, Carson KR, Gage BF. Sanfilippo KM, et al. Am J Hematol. 2019 Nov;94(11):1176-1184. doi: 10.1002/ajh.25603. Epub 2019 Aug 19. Am J Hematol. 2019. PMID: 31379000 Free PMC article.
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-ri …
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The Inter …
Dysproteinemia and the Kidney: Core Curriculum 2019.
Hogan JJ, Alexander MP, Leung N. Hogan JJ, et al. Am J Kidney Dis. 2019 Dec;74(6):822-836. doi: 10.1053/j.ajkd.2019.04.029. Epub 2019 Jul 19. Am J Kidney Dis. 2019. PMID: 31331759 Review.
The underlying clonal disorder may meet criteria for overt multiple myeloma or systemic lymphoma. In recent years, there has been increased recognition and study of dysproteinemic kidney diseases that occur in the setting of smaller clonal plasma and B-cell p …
The underlying clonal disorder may meet criteria for overt multiple myeloma or systemic lymphoma. In recent years, there has b …
Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016.
Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J, Wang L; Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology; Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology. Liu J, et al. J Hematol Oncol. 2019 Dec 10;12(1):136. doi: 10.1186/s13045-019-0807-5. J Hematol Oncol. 2019. PMID: 31823802 Free PMC article.
BACKGROUND: The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in China. ...RESULTS: It was estimated that there were 16,500 new cases and 10,300 deaths of multiple myeloma in China in 2016. …
BACKGROUND: The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in …
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
International Myeloma Working Group. International Myeloma Working Group. Br J Haematol. 2003 Jun;121(5):749-57. Br J Haematol. 2003. PMID: 12780789 Free article.

In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is < 30 g/l and the bone marrow clonal cells < 10% with no evidence of multiple myeloma, other B-cell proliferative

…
In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal pro …
2,368 results